124 related articles for article (PubMed ID: 33382015)
1. Computational-aided design: minimal peptide sequence to block dengue virus transmission into cells.
Arumugam AC; Agharbaoui FE; Khazali AS; Yusof R; Abd Rahman N; Ahmad Fuaad AAH
J Biomol Struct Dyn; 2022 Jul; 40(11):5026-5035. PubMed ID: 33382015
[TBL] [Abstract][Full Text] [Related]
2. Hit-to-Lead Short Peptides against Dengue Type 2 Envelope Protein: Computational and Experimental Investigations.
Zaidi NJ; Abdullah AA; Heh CH; Lin CH; Othman R; Ahmad Fuaad AAH
Molecules; 2022 May; 27(10):. PubMed ID: 35630712
[TBL] [Abstract][Full Text] [Related]
3. Dynamics and binding interactions of peptide inhibitors of dengue virus entry.
Isa DM; Chin SP; Chong WL; Zain SM; Rahman NA; Lee VS
J Biol Phys; 2019 Mar; 45(1):63-76. PubMed ID: 30680580
[TBL] [Abstract][Full Text] [Related]
4. Conformational and energy evaluations of novel peptides binding to dengue virus envelope protein.
Amir-Hassan A; Lee VS; Baharuddin A; Othman S; Xu Y; Huang M; Yusof R; Rahman NA; Othman R
J Mol Graph Model; 2017 Jun; 74():273-287. PubMed ID: 28458006
[TBL] [Abstract][Full Text] [Related]
5. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the mode of action of a potent dengue virus capsid inhibitor.
Scaturro P; Trist IM; Paul D; Kumar A; Acosta EG; Byrd CM; Jordan R; Brancale A; Bartenschlager R
J Virol; 2014 Oct; 88(19):11540-55. PubMed ID: 25056895
[TBL] [Abstract][Full Text] [Related]
7. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222
[TBL] [Abstract][Full Text] [Related]
9. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus.
Tahir Ul Qamar M; Maryam A; Muneer I; Xing F; Ashfaq UA; Khan FA; Anwar F; Geesi MH; Khalid RR; Rauf SA; Siddiqi AR
Sci Rep; 2019 Feb; 9(1):1433. PubMed ID: 30723263
[TBL] [Abstract][Full Text] [Related]
10. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections.
Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I
Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking, simulations of animal peptides against the envelope protein of Dengue virus.
Guntamadugu R; Ramakrishnan R; Darala G; Kothandan S
J Biomol Struct Dyn; 2023 Nov; ():1-15. PubMed ID: 37929876
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of dengue-virus entry.
Schmidt AG; Lee K; Yang PL; Harrison SC
PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653
[TBL] [Abstract][Full Text] [Related]
13. Peptide inhibitors of flavivirus entry derived from the E protein stem.
Schmidt AG; Yang PL; Harrison SC
J Virol; 2010 Dec; 84(24):12549-54. PubMed ID: 20881042
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
15. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation.
Ahmed M; Kumar A; Hobman TC; Barakat K
J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
17. Identification of neo-andrographolide compound targeting NS1 Lys14: an important residue in NS1 activity driving dengue pathogenesis.
Elumalai E; Suresh Kumar M
J Biomol Struct Dyn; 2023 Jul; 41(10):4504-4514. PubMed ID: 35491708
[TBL] [Abstract][Full Text] [Related]
18. Targeting a conserved pocket (n-octyl-β-D-glucoside) on the dengue virus envelope protein by small bioactive molecule inhibitors.
Naresh P; Selvaraj A; Shyam Sundar P; Murugesan S; Sathianarayanan S; Namboori P K K; Jubie S
J Biomol Struct Dyn; 2022 Jul; 40(11):4866-4878. PubMed ID: 33345726
[TBL] [Abstract][Full Text] [Related]
19. Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptide.
Rothan HA; Mohamed Z; Suhaeb AM; Rahman NA; Yusof R
OMICS; 2013 Nov; 17(11):560-7. PubMed ID: 24044366
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Perspectives in the Discovery of Dengue Virus Entry Inhibitors.
Gallo FN; Enderle AG; Pardo LA; Leal ES; Bollini M
Curr Med Chem; 2022; 29(4):719-740. PubMed ID: 34036904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
